Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:activities |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2000
gptkb:2017 gptkb:FDA |
| gptkbp:class |
gptkb:monoclonal_antibody
|
| gptkbp:clinical_trial |
Phase II
first-line therapy NC T00003483 NC T00003500 NC T00003501 NC T00003502 NC T00003503 |
| gptkbp:contraindication |
hypersensitivity to the drug
severe liver impairment active infection |
| gptkbp:dosage_form |
lyophilized powder
|
| gptkbp:financial_products |
D B01280
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mylotarg
|
| gptkbp:indication |
relapsed acute myeloid leukemia
|
| gptkbp:ingredients |
gptkb:gemtuzumab_ozogamicin
C_34 H_46 N_4 O_10 S |
| gptkbp:interacts_with |
gptkb:warfarin
live vaccines other immunosuppressants CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 X X32
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
treatment of acute myeloid leukemia
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:monitors |
0 A0 D1 F1 D1 D
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
clearance 0.03 L/h/kg
half-life 48 hours volume of distribution 0.1 L/kg |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:replaced_by |
gptkb:2010
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache muscle pain nausea fever vomiting diarrhea rash chills thrombocytopenia hepatotoxicity infusion reactions febrile neutropenia |
| gptkbp:storage |
2-8° C
|
| gptkbp:targets |
C D33
|
| gptkbp:type_of |
176477-41-0
|